Stifel Starts Neurogene (NGNE) at Buy, 'Differentiated Rett Gene Therapy and Platform With Initial Data Late 2024'
Tweet Send to a Friend
(Updated - January 5, 2024 4:18 AM EST)
Stifel analyst Paul Matteis initiates coverage on Neurogene (NASDAQ: NGNE) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Paul Matteis initiates coverage on Neurogene (NASDAQ: NGNE) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
